Immutep (ASX:IMM) received roughly AU$3.6 million in research and development-related tax incentives from the French government, according to a Tuesday filing with the Australian bourse.
The ASX-listed biotechnology company received the payment through its subsidiary, Immutep SAS. Under the French government's Research Tax Credit scheme, French companies conducting research and development activities in Europe can be reimbursed 30% of their eligible expenditure, the filing stated.
Immutep said it will use the funds for the global clinical development of eftilagimod alpha and IMP761.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。